COPD
COPD Exacerbation Antibiotics
search
COPD Exacerbation Antibiotics
, Antibiotic Use in COPD Exacerbation
See Also
Acute Exacerbation of Chronic Bronchitis
Acute Respiratory Failure
COPD
Chronic Bronchitis
Emphysema
Alpha-1-Antitrypsin Deficiency
COPD Staging
COPD Management
COPD Exacerbation Prevention
COPD Action Plan
Indications
Antibiotic
indications if 3 criteria met
Increased
Dyspnea
(or requiring
NIPPV
or Intubation)
Increased
Sputum
Purulent Sputum
Management
Antibiotic
s for Uncomplicated
Chronic Bronchitis
See
Acute Exacerbation of Chronic Bronchitis
for other management (e.g.
Corticosteroid
s,
Bronchodilator
s)
Criteria
Under age 65 years old
FEV1
> 50% of predicted
Under 4 acute exacerbations per year
No significant comorbid disease
Coverage
Haemophilus Influenzae
Streptococcus Pneumoniae
Moraxella catarrhalis
Chlamydia pneumoniae
Mycoplasma pneumoniae
Antibiotic
s (5 day course)
First-Line
Trimethoprim-Sulfamethoxazole (
Bactrim
DS,
Septra
DS) one tablet orally twice daily
Amoxicillin
1000 mg orally twice daily
Equivalent to
Moxifloxacin
in clinical outcome
Wilson (2004) Chest 125:953-64 [PubMed]
Other
Antibiotic
s
Doxycycline
100 mg orally twice daily
No longer recommended in
COPD
exacerbation due to lack of efficacy
Sethi and Murphy in Ramirez, Management of infection in exacerbations of
COPD
, UpToDate, accessed 11/24/2022
van Velzen (2017) Lancet Respir Med 5(6):492-9 +PMID: 28483402 [PubMed]
Management
Antibiotic
s for Complicated
Chronic Bronchitis
See
Acute Exacerbation of Chronic Bronchitis
for other management (e.g.
Corticosteroid
s,
Bronchodilator
s)
Criteria
Uncomplicated criteria not met (see above)
Coverage
Uncomplicated
Chronic Bronchitis
Bacteria
(see above)
Gram Negative Rod
s (e.g.
Pseudomonas
)
Dosing for 5 day course
Amoxicillin
-Clavulanate (
Augmentin
) 875 mg orally twice daily
Second generation
Macrolide
Clarithromycin
(
Biaxin
) 500 mg orally twice daily
Azithromycin
(
Zithromax
) 500 mg day 1, then 250 mg PO x4 days
Also available as 3 day preparation
Similar outcomes to
Levofloxacin
for 7 days
Amsden (2003) Chest 123:772-7 [PubMed]
Fluoroquinolone
Levofloxacin
(
Levaquin
) 750 mg orally daily
Moxifloxacin
(
Avelox
) 400 mg orally daily
Cephalosporin
s (alternative agents)
Cefuroxime Axetil
250 to 500 mg orally every 12 hours
Cefprozil
500 mg orally every 12 hours
Cefdinir
300 mg every 12 hours (or 600 mg every 24 hours)
Cefpodoxime Proxetil
200 mg every 12 hours
Management
Antibiotic
s for Severe Exacerbation requiring hospitalization
See
Acute Respiratory Failure
Co-administer
Corticosteroid
s
Initially use intravenous
Corticosteroid
s
Methylprednisolone
(Solumedrol) 60 mg IV every 6 hours
Avoid high doses (e.g. 125 mg) as they offer no added benefit
Transition to oral
Corticosteroid
s as soon as prudent
Prednisone
30-40 mg orally daily
Taper off over 2 weeks (no benefit to previously used longer taper over 8 weeks)
Low risk for
Pseudomonas
Consider Outpatient
Antibiotic
s for Complicated
Chronic Bronchitis
as above
Ceftriaxone
(
Rocephin
) 1 to 2 grams IV every 24 hours
Cefotaxime
(
Claforan
) 1 gram IV every 8-12 hours
Levofloxacin
(
Levaquin
) 750 mg IV or orally every 24 hours
Moxifloxacin
(
Avelox
) 400 mg IV or orally daily
Higher risk for
Pseudomonas
Piperacillin
-Tazobactam (
Zosyn
) 3.375 g IV q6 hours
Levofloxacin
(
Levaquin
) 750 mg IV or orally every 24 hours
Cefepime
2 g IV every 24 hours
Ceftazidime
(
Fortaz
) 1-2 grams IV every 8-12 hours
Two
Parenteral
drug combination (older regimen, replaced by other agents)
Drug 1:
Cephalosporin
or
Antipseudomonal Penicillin
Drug 2:
Fluoroquinolone
or
Aminoglycoside
Tobramycin
(
Tobrex
)
Split dosing: 1 mg/kg IV q8-12 hours
Once daily: 5 mg/kg IV q24 hours
Efficacy
Inconsistent outcomes with and without
Antibiotic
s in AECB
Vollenweider (2018) Cochrane Database Syst Rev 10(10):CD010257 +PMID: 30371937 [PubMed]
Lower
COPD
exacerbation treatment failure rate when
Antibiotic
s are used in exacerbation that meets criteria
Suzuki (2024) Respir Investig 62(4):663-8 +PMID: 38761481 [PubMed]
References
(2025) Sanford Guide, accessed on IOS, 5/1/2025
Stoller and Hatipoglu (2025)
COPD Exacerbation Management
, UpToDate, accessed on IOS, 5/1/2025
Type your search phrase here